Belen Morenes - Grifols S Independent Director

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GS</div>
GRFS -- USA Stock  

Report: 29th of July 2020  

Ms. Belen Villalonga Morenes serves as Independent Director of Grifols, S.A. since May 24, 2013. She is an Associate Professor with Tenure at New York University Stern School of Business. Between 2001 and 2012, she was a faculty member at Harvard Business School. She serves as an independent director at Acciona, leader in the renewable energy and infrastructure businesses, since 2006, and at Talgo, a highspeed train manufacturer, since 2015. She is also a Senior Associate Partner at Cambridge Advisors to Family Enterprise, a family business consulting company. Her teaching, research, and consulting activities are in the areas of corporate strategy, finance, and governance, with a special focus on familycontrolled companies. Her awardwinning research, which was published in the top academic journals, was cited extensively in academic articles and in the international media. She holds a Bachelors degree in Economics from Universidad Complutense de Madrid, Doctorate in Philosophy degree in Business Science from Universidad Complutense de Madrid, Masters degree in Economics from University of California, Los Angeles, Doctorate in Philosophy degree in Economics from Universidad Complutense de Madrid and Doctorate in Philosophy in Business Administration from University of California, Los Angeles.
Age: 45  Director Since 2013      
34 93 571 00 00

Grifols S Management Efficiency

Grifols S A has return on total asset (ROA) of 4.97 % which means that it generated profit of $4.97 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 12.21 %, meaning that it created $12.21 on every $100 dollars invested by stockholders. Grifols S management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. As of 07/10/2020, Return on Average Assets is likely to grow to 0.05. Also, Return on Average Equity is likely to grow to 0.16Grifols S Asset Turnover is relatively stable at the moment as compared to the past year. Grifols S reported last year Asset Turnover of 0.36. As of 07/10/2020, Return on Average Assets is likely to grow to 0.05, while Total Assets are likely to drop slightly above 12.8 B. As of 07/10/2020, Tax Liabilities is likely to grow to about 489 M, while Total Liabilities is likely to drop slightly above 7.5 B.
The company currently holds 7.41 B in liabilities with Debt to Equity (D/E) ratio of 1.0, which is about average as compared to similar companies. Grifols S A has a current ratio of 2.7, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Similar Executives

Showing few of many executives


Karen VousdenBristol Myers Squibb
Manvinder BangaGlaxoSmithKline PLC
Nicholas MooreGilead Sciences
Robert BertoliniBristol Myers Squibb
Laurie GlimcherBristol Myers Squibb
Gayle WilsonGilead Sciences
Jacqueline BartonGilead Sciences
Matthew EmmensBristol Myers Squibb
Mary BeckerleJohnson Johnson
Raul AlvarezEli Lilly And
Roy AndersonGlaxoSmithKline PLC
Elizabeth DohertyNovartis AG
Lewis CampbellBristol Myers Squibb
Ralph AlvarezEli Lilly And
Stephanie BurnsGlaxoSmithKline PLC
Marschall RungeEli Lilly And
Deryck MaughanGlaxoSmithKline PLC
Lynn ElsenhansGlaxoSmithKline PLC
Laurie GlimcherGlaxoSmithKline PLC
Leslie BrunMerck Company
William WaldegraveGW Pharmaceuticals Plc

Company Summary

Grifols, S.A. develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company was founded in 1940 and is headquartered in Barcelona, Spain. Grifols S operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 24040 people.Grifols S A (GRFS) is traded on BATS Exchange in USA. It is located in Avinguda de la Generalitat, 152 and employs 24,040 people. Grifols S is listed under Pharmaceutical Products category by Fama And French industry classification.

Grifols S A Leadership Team

Antonio Pares, Director of Planning and Control
Carsten Schroeder, President Of The Diagnostic Division
Albert Roura, CEO of Laboratorios Grifols SA
Lafmin Morgan, President Of The Bioscience And Hospital Division
Juan Roura, Vice President of Production, Executive Director
Eva Tubau, Chief Scientific Officer
Anna Lluch, Independent Director
Carlos Fernandez, Deputy Industrial Vice President
Jose Gras, Director, Representative of Thorthol Holdings BV
Edgar Jannotta, Independent Director
Vicente Torre, CTO
Mateo Humbert, Director of Human Resources
Montserrat Calvo, Chief Administrative Officer, Controller
Ramon Roca, Vice-President of Marketing and Sales and Executive Director
David Bell, Vice President of Corporate Operations and Development of Grifols Inc and United States Subsidiaries
Victor Deu, Co-CEO, Executive Director
Luis Bobadilla, Independent Director
Inigo Mardones, Director
Thomas Glanzmann, Director
Carina Lazaro, Independent Director
Joel Abelson, President of North America Commercial Division of Grifols Inc
Steven Mayer, Director
Javier Ribes, CEO of Instituto Grifols SA
Alfredo Guerra, CFO and Corporate VP
Raimon Roura, Non-Member Secretary of the Board
Victor Roura, Chairman, CEO and President and Member of Appointments and Remuneration Committee
Brett Ingersoll, Director
Shinji Wada, President of Plasma Centers of Grifols Inc
Tomas Gelabert, Director
Marla Salmon, Independent Director
Nuria Barnes, Non-Member Assistant Secretary of the Board
Gregory Rich, President of Grifols Inc and Subsidiaries in the US
Belen Morenes, Independent Director
Nuria Lapena, Director of Shareholder and Investor Relations

Stock Performance Indicators

Did you try this?

Run Headlines Timeline Now


Headlines Timeline

Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Please also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page